Health Condition 1: L405- Arthropathic psoriasis Health Condition 2: M138- Other specified arthritis Health Condition 3: null- Psoriatic arthritis
Conditions
Interventions
Intervention1: group 1: Methotrexate, starting dose 10 mg/week orally for 2 weeks , if minimum disease activity is not achieved in 2 weeks dose will be increased 5 mg every 2 weeks until minimum disea
Sponsors
JIPMER intramural fund
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients satisfying CASPAR criteria for Psoriatic Arthritis 2. At least 3 peripheral joints with active arthritis 3. DMARD naïve patients
Exclusion criteria
Exclusion criteria: 1. End stage disease (deformed fixed joints) 2. Contraindications to DMARD therapy (Chronic alcoholism, chronic liver disease, evidence of acute/chronic infection, chronic kidney disease, patients with leucopenia ( 2Ã? upper normal value and creatinine clearance 3. Pregnant or lactating women; patients (both men and women) of reproductive age group unwilling for contraceptive use who have not completed the family 4. Psoriatic arthritis with only axial involvement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse drug reactions and Response to treatment - by PsARC criteria Timepoint: PsARC criteria at 24 weeks of starting treatment Adverse reaction during the study | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Functional ability â?? iHAQ b. ACR 20 and ACR 50 response criteria c. PASI score d. DAPSA score e. Percentage of patients attaining MDA in each group f. Changes in serum interleukin (IL-1α), interleukin 1 β (IL-1β) , interleukin-6(IL-6) and tumor necrosis factor α(TNF-α) Timepoint: base line and 6 months | — |
Countries
India
Contacts
Public ContactDr Shanoj K C
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed